What every nephrologist needs to know about hydroxychloroquine toxicity


Area of Science:

• Nephrology and Rheumatology
• Pharmacology
• Autoimmune Disease Management

Background:

• Hydroxychloroquine (HCQ) is a widely used medication for rheumatologic manifestations of systemic lupus erythematosus (SLE) and other autoimmune disorders.
• Rheumatologists frequently manage HCQ therapy, often initiating treatment for patients.
• Nephrologists report less familiarity and comfort with managing the multifaceted effects of HCQ.

Observation:

• A case is presented where a nephrologist abdicated responsibility for HCQ management initiated by a rheumatologist.
• This abdication of responsibility led to devastating consequences for the patient.
• The scenario highlights a gap in collaborative patient care between rheumatologists and nephrologists regarding HCQ.

Findings:

• Nephrologists' reluctance to manage HCQ can stem from a lack of comfort with its complex effects.
• Patient outcomes can be severely compromised when HCQ management is not comprehensively addressed by the treating nephrologist.
• Effective management of HCQ requires a collaborative approach involving both specialties.

Implications:

• Encouraging greater nephrologist involvement in HCQ management is essential for improving patient safety and outcomes.
• Educational initiatives may be needed to enhance nephrologists' confidence and competence in managing HCQ.
• This case underscores the critical need for interdisciplinary communication and shared responsibility in managing patients on HCQ therapy.